N. Basara et al., Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study, BONE MAR TR, 25(4), 2000, pp. 371-376
Citations number
25
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Mobilization of peripheral blood cell progenitor cells was investigated in
36 healthy sibling donors using three different split doses of glycosylated
rhG-CSF (lenograstim), The donors were randomized into three groups: group
1 was given lenograstim at 8, group 2 at 11 and group 3 at 15 mu g/kg/day
in two split doses, subcutaneously for 4 and 5 days, respectively. Leukaphe
resis was performed on day 4 or 5 depending on the WBC and CD34(+) cell cou
nt. We were able to demonstrate that there was a significant correlation be
tween circulating CD34(+) cells on the day of harvest and CD34(+) cells in
the apheresis products in all three groups. The number of CD34(+) cells pre
-apheresis was inversely correlated with age in group 1 and group 2, Howeve
r, in group 3, the number of CD34(+) sells preapheresis did not correlate w
ith age. There was also a difference between the number of progenitor cells
mobilized in the three dose groups regarding the time of harvest. Apheresi
s was performed in groups 1 and 2 on day 5 of mobilization in order to obta
in a sufficient number of stem cells for allogeneic transplantation. In con
trast, with the split dose of 15 mu g/kg/day, harvest could be routinely pe
rformed on day 4 of stimulation. We conclude that lenograstim given twice a
day at doses of 8, 11 and 15 mu g/kg/day provided different CD34(+) cell y
ields in normal donors, in particular, with regard to the time of harvest.
The number of CD34(+) cells preapheresis was not correlated with age in the
group of donors mobilized with a split dose of 15 mu g/kg/day, indicating
that this dosage might also be suitable for older donors.